Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Calpains mediate axonal cytoskeleton disintegration during Wallerian degeneration.

Neurobiology of disease | 2013

In both the central nervous system (CNS) and peripheral nervous system (PNS), transected axons undergo Wallerian degeneration. Even though Augustus Waller first described this process after transection of axons in 1850, the molecular mechanisms may be shared, at least in part, by many human diseases. Early pathology includes failure of synaptic transmission, target denervation, and granular disintegration of the axonal cytoskeleton (GDC). The Ca(2+)-dependent protease calpains have been implicated in GDC but causality has not been established. To test the hypothesis that calpains play a causal role in axonal and synaptic degeneration in vivo, we studied transgenic mice that express human calpastatin (hCAST), the endogenous calpain inhibitor, in optic and sciatic nerve axons. Five days after optic nerve transection and 48 h after sciatic nerve transection, robust neurofilament proteolysis observed in wild-type controls was reduced in hCAST transgenic mice. Protection of the axonal cytoskeleton in sciatic nerves of hCAST mice was nearly complete 48 h post-transection. In addition, hCAST expression preserved the morphological integrity of neuromuscular junctions. However, compound muscle action potential amplitudes after nerve transection were similar in wild-type and hCAST mice. These results, in total, provide direct evidence that calpains are responsible for the morphological degeneration of the axon and synapse during Wallerian degeneration.

Pubmed ID: 23542511 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: F31 NS071804
  • Agency: NINDS NIH HHS, United States
    Id: K08 NS065157
  • Agency: NIAMS NIH HHS, United States
    Id: P30 AR050950
  • Agency: NINDS NIH HHS, United States
    Id: K08NS065157
  • Agency: NINDS NIH HHS, United States
    Id: F31NS071804
  • Agency: NIAMS NIH HHS, United States
    Id: P30AR050950
  • Agency: NINDS NIH HHS, United States
    Id: T32 NS077889
  • Agency: NINDS NIH HHS, United States
    Id: P01NS058484
  • Agency: NINDS NIH HHS, United States
    Id: P01 NS058484
  • Agency: NINDS NIH HHS, United States
    Id: K08 NS055880
  • Agency: NINDS NIH HHS, United States
    Id: K08NS055880

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Jackson ImmunoResearch (tool)

RRID:SCR_010488

A commercial antibody vendor, specializing in secondary antibodies.

View all literature mentions